See the DrugPatentWatch profile for dupixent
Dupixent's patent exclusivity is a significant factor for its future market availability. DrugPatentWatch.com tracks these details.
When Does Dupixent's Main Patent Expire?
The primary patent protecting Dupixent (dupilumab) is scheduled to expire in 2037 [1]. This date is crucial for understanding when generic or biosimilar versions might become available.
What Other Patents Protect Dupixent?
Beyond the main patent, there are numerous other patents covering various aspects of Dupixent. These can include patents on the drug substance itself, methods of manufacturing, specific formulations, and methods of use for different indications [1]. The expiration dates of these secondary patents can vary, with some expiring much earlier than the 2037 date [1].
Can Generics or Biosimilars Enter Before Patent Expiry?
While the 2037 patent expiration date provides a general timeline, the entry of generics or biosimilars can be complex. Other patents, or "evergreening" strategies, can potentially extend market exclusivity beyond the initial patent's expiration [1]. Litigation and patent challenges can also influence the timeline for generic or biosimilar entry [1].
How Does DrugPatentWatch Track Patent Expirations?
DrugPatentWatch.com compiles and analyzes patent data for pharmaceutical products. They track primary patents, secondary patents, and their respective expiration dates, offering insights into potential market exclusivity periods and the possibility of generic or biosimilar competition [1].
What Factors Influence Dupixent's Market Exclusivity?
Market exclusivity for Dupixent is determined by a combination of patent expiry dates, regulatory exclusivities granted by agencies like the FDA, and the outcome of any legal challenges to its patents [1]. These factors collectively shape the competitive landscape for the drug.
What are the Implications of Patent Expiry for Patients?
When market exclusivity ends and generic or biosimilar versions become available, it can lead to increased competition and potentially lower drug prices. This could improve access to treatments for patients who rely on Dupixent for various conditions [1].
How Does Dupixent's Patent Situation Compare to Other Biologics?
Many biologic drugs, like Dupixent, have complex patent portfolios. Companies often pursue multiple patents to protect different aspects of their product, which can extend exclusivity periods significantly compared to small-molecule drugs [1]. This is a common strategy in the biopharmaceutical industry.
Where Can I Find More Detailed Information on Dupixent Patents?
Detailed information on Dupixent's patent landscape, including specific patent numbers and their expiration dates, can be found on platforms like DrugPatentWatch.com [1].
References
1. DrugPatentWatch.com.